ALDX
Aldeyra Therapeutics, Inc. NASDAQ Listed May 2, 2014$1.73
Pre-mkt
$1.71
-2.84%
Mkt Cap $104.4M
52w Low $1.07
12.9% of range
52w High $6.17
50d MA $2.62
200d MA $4.53
P/E (TTM)
-2.8x
EV/EBITDA
-8.1x
P/B
2.2x
Debt/Equity
0.3x
ROE
-76.5%
P/FCF
0.0x
RSI (14)
—
ATR (14)
—
Beta
1.33
50d MA
$2.62
200d MA
$4.53
Avg Volume
3.1M
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical trial for psoriasis, asthma, and COVID-19; and ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of retinitis pigmentosa, as well as for treating primary vitreoretinal lymphoma. The company has a license agreement with Madrigal Pharmaceuticals, Inc. for developing ADX-1612, which inhibits the protein chaperome for the treatment of inflammatory diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
131 Hartwell Avenue · Lexington, MA 02421 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 27, 2026 | AMC | -0.14 | -0.11 | +21.4% | 5.46 | -1.1% | +2.9% | -9.1% | +1.8% | -10.6% | +3.2% | — |
| Nov 5, 2025 | AMC | -0.17 | -0.13 | +23.5% | 4.93 | +0.2% | -2.4% | -2.5% | +9.4% | +1.9% | +1.3% | — |
| Aug 7, 2025 | AMC | -0.21 | -0.16 | +23.8% | 5.17 | -0.2% | +1.7% | -0.2% | +2.1% | +0.2% | -1.3% | — |
| May 14, 2025 | AMC | -0.25 | -0.17 | +32.0% | 2.17 | +0.9% | -0.5% | +0.0% | +12.0% | -2.5% | -4.7% | — |
| Feb 28, 2025 | AMC | -0.25 | -0.27 | -8.0% | 5.11 | +2.5% | +18.6% | +1.8% | -0.3% | +2.3% | +1.0% | — |
| Nov 7, 2024 | AMC | -0.25 | -0.25 | +0.0% | 5.34 | +0.6% | +3.4% | -0.5% | -13.3% | -7.4% | -3.2% | — |
| Aug 1, 2024 | AMC | -0.14 | -0.28 | -100.0% | 3.71 | -5.9% | -5.1% | -8.2% | +6.5% | -5.2% | +28.5% | — |
| May 2, 2024 | AMC | -0.08 | -0.14 | -75.0% | 4.21 | +0.5% | -1.2% | -1.0% | +1.2% | -2.4% | -3.2% | — |
| Mar 7, 2024 | AMC | -0.21 | -0.08 | +61.9% | 3.85 | -1.8% | -6.0% | -10.2% | -7.4% | -3.7% | -4.5% | — |
| Nov 3, 2023 | AMC | -0.24 | -0.14 | +41.7% | 2.21 | +0.4% | +1.8% | +23.1% | -5.8% | -9.8% | -3.0% | — |
| Aug 3, 2023 | AMC | -0.31 | -0.15 | +51.6% | 7.92 | +2.0% | +1.4% | -6.2% | -1.2% | +1.9% | +0.5% | — |
| May 4, 2023 | AMC | -0.30 | -0.27 | +10.0% | 10.39 | +0.7% | +1.7% | +0.9% | -3.8% | -0.3% | +1.2% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 18 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $1.24 | $1.20 | -3.2% | +14.5% | +28.9% | -1.1% | +23.2% | -16.1% |
| Nov 10 | BTIG | Maintains | Buy → Buy | — | $4.69 | $4.74 | +1.1% | +9.4% | +1.9% | +1.3% | -5.3% | +0.6% |
| May 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.16 | $2.15 | -0.5% | +12.0% | -2.5% | -4.7% | +0.0% | -1.3% |
| Apr 7 | BTIG | Maintains | Buy → Buy | — | $1.89 | $1.80 | -4.8% | +3.2% | -1.5% | +1.0% | -2.6% | +1.1% |
| Apr 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.42 | $1.40 | -1.4% | +33.1% | +3.2% | -1.5% | +1.0% | -2.6% |
| Mar 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.11 | $5.24 | +2.5% | +18.6% | +1.8% | -0.3% | +2.3% | +1.0% |
| Aug 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.19 | $4.19 | +0.0% | +21.7% | -6.9% | -0.8% | -0.4% | +11.9% |
| Aug 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.71 | $3.49 | -5.9% | -5.1% | -8.2% | +6.5% | -5.2% | +28.5% |
| May 6 | Oppenheimer | Maintains | Outperform → Outperform | — | $4.16 | $4.16 | +0.0% | -1.0% | +1.2% | -2.4% | -3.2% | -4.3% |
| May 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.16 | $4.16 | +0.0% | -1.0% | +1.2% | -2.4% | -3.2% | -4.3% |
| Apr 3 | Oppenheimer | Upgrade | Perform → Outperform | — | $3.55 | $3.65 | +2.8% | +16.9% | +12.8% | +0.9% | -7.2% | +1.1% |
| Oct 17 | Oppenheimer | Downgrade | Outperform → Perform | — | $1.83 | $1.80 | -1.6% | +0.5% | -6.0% | -4.0% | -0.6% | -9.7% |
| Oct 17 | Citigroup | Maintains | Buy → Buy | — | $1.83 | $1.80 | -1.6% | +0.5% | -6.0% | -4.0% | -0.6% | -9.7% |
| Aug 9 | Oppenheimer | Maintains | Outperform → Outperform | — | $7.44 | $7.43 | -0.1% | +1.9% | +0.5% | +0.9% | -0.3% | +2.5% |
| Jun 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.90 | $8.06 | +2.0% | +6.2% | -4.9% | -1.9% | -0.9% | -0.6% |
| Jun 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.72 | $7.90 | +2.3% | +0.4% | -8.3% | +5.6% | -0.7% | +3.6% |
| Jun 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.87 | $10.96 | +0.8% | -3.2% | +1.1% | -27.4% | +0.4% | -8.3% |
| Jun 1 | Citigroup | Maintains | Buy → Buy | — | $9.49 | $9.45 | -0.4% | +9.3% | +2.7% | +6.6% | -0.4% | +1.6% |
| May 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.39 | $10.46 | +0.7% | +1.7% | +0.9% | -3.8% | -0.3% | +1.2% |
| Mar 10 | Citigroup | Maintains | Buy → Buy | — | $7.90 | $8.00 | +1.3% | -9.1% | -2.2% | +12.0% | -0.6% | +1.9% |
| Mar 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.90 | $8.00 | +1.3% | -9.1% | -2.2% | +12.0% | -0.6% | +1.9% |
| Mar 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.76 | $6.80 | +0.6% | +4.9% | +5.8% | -0.3% | -1.6% | -2.0% |
| Nov 21 | Citigroup | Maintains | Buy → Buy | — | $5.19 | $5.19 | +0.0% | -0.6% | +2.7% | +1.5% | +1.5% | -4.8% |
| Jun 9 | Citigroup | Maintains | Buy → Buy | — | $3.50 | $3.59 | +2.6% | +10.3% | -7.5% | -6.4% | +3.6% | -2.6% |
| Dec 21 | SVB Leerink | Maintains | Outperform → Outperform | — | $7.13 | $4.00 | -43.9% | -50.9% | +9.7% | +8.6% | -2.2% | -0.5% |
| Dec 21 | Citigroup | Maintains | Buy → Buy | — | $7.13 | $4.00 | -43.9% | -50.9% | +9.7% | +8.6% | -2.2% | -0.5% |
| Apr 28 | Citigroup | Maintains | Buy → Buy | — | $14.85 | $14.13 | -4.8% | -6.2% | -10.2% | +0.5% | -0.6% | -4.0% |
| Mar 12 | SVB Leerink | Maintains | Outperform → Outperform | — | $12.07 | $12.00 | -0.6% | +3.7% | -4.3% | -2.3% | +5.3% | -5.8% |
| Mar 12 | Citigroup | Maintains | Buy → Buy | — | $12.07 | $12.00 | -0.6% | +3.7% | -4.3% | -2.3% | +5.3% | -5.8% |
| Feb 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.59 | $13.00 | +3.3% | -2.8% | -2.0% | -2.8% | +1.5% | +7.4% |
| Dec 16 | Berenberg | Maintains | Buy → Buy | — | $6.89 | $7.19 | +4.4% | +5.8% | +3.3% | +0.0% | +8.0% | -7.6% |
| Oct 30 | Jefferies | Maintains | Buy → Buy | — | $6.31 | $6.96 | +10.3% | +5.9% | -2.2% | +1.8% | +2.1% | +2.4% |
| Oct 16 | BTIG | Maintains | Buy → Buy | — | $6.86 | $7.33 | +6.9% | +18.1% | -1.9% | -4.7% | -6.3% | +6.9% |
| Aug 11 | Citigroup | Maintains | Buy → Buy | — | $6.89 | $6.91 | +0.3% | -4.1% | +1.7% | +0.3% | -1.8% | +4.2% |
| May 12 | Oppenheimer | Maintains | Outperform → Outperform | — | $2.96 | $3.50 | +18.2% | +13.2% | +6.0% | +5.6% | +20.0% | -6.7% |
| Dec 4 | Citigroup | Maintains | Buy → Buy | — | $9.26 | $9.56 | +3.2% | +8.4% | -1.9% | -6.3% | +1.1% | +1.7% |
| Sep 26 | Stifel Nicolaus | Maintains | Buy → Buy | — | $9.90 | $12.35 | +24.7% | +34.8% | +7.5% | -3.8% | -5.4% | +1.8% |
| Sep 26 | Stifel | Maintains | Buy → Buy | — | $9.90 | $12.35 | +24.7% | +34.8% | +7.5% | -3.8% | -5.4% | +1.8% |
| Sep 13 | Janney Capital | Maintains | Buy → Buy | — | $8.00 | $8.20 | +2.5% | -2.5% | +0.6% | -2.5% | +2.6% | +2.5% |
| Jan 26 | Seaport Global | Maintains | Buy → Buy | — | $7.25 | $7.40 | +2.1% | +2.8% | +2.0% | -0.3% | -1.3% | +0.3% |
| Oct 25 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $6.20 | $6.90 | +11.3% | +3.2% | -2.3% | +1.6% | -1.6% | +0.8% |
| Sep 13 | Canaccord Genuity | Maintains | Buy → Buy | — | $5.65 | $6.35 | +12.4% | +12.4% | +70.1% | -17.6% | +2.2% | -20.3% |
| Sep 26 | H.C. Wainwright | Maintains | Buy → Buy | — | $7.45 | $7.60 | +2.0% | +3.4% | +0.6% | -3.4% | +0.4% | +4.0% |
| Jul 1 | Stifel Nicolaus | Maintains | Buy → Buy | — | $5.69 | $5.87 | +3.2% | +6.3% | +1.5% | +3.1% | +5.4% | +1.9% |
| Sep 8 | Cowen & Co. | Maintains | Outperform → Outperform | — | $7.08 | $7.50 | +5.9% | +1.1% | -2.0% | -2.8% | +2.3% | -2.0% |
| Jul 1 | Canaccord Genuity | Maintains | Buy → Buy | — | $7.76 | $8.34 | +7.5% | +7.1% | +2.3% | -1.5% | +1.3% | -6.5% |
| May 27 | Janney Capital | Maintains | Buy → Buy | — | $6.87 | $7.05 | +2.6% | +8.7% | +0.3% | -0.5% | +1.6% | +0.4% |
| Mar 25 | Chardan Capital | Maintains | Buy → Buy | — | $10.61 | $10.75 | +1.3% | +0.3% | -2.2% | +3.3% | -5.9% | +0.6% |
| Jan 26 | Laidlaw & Co. | Maintains | Buy → Buy | — | $8.86 | $9.44 | +6.5% | +11.3% | +11.3% | +5.7% | +2.2% | +2.2% |
| Dec 3 | Ascendiant Capital | Maintains | Buy → Buy | — | $7.26 | $7.64 | +5.2% | +4.0% | -2.1% | -2.7% | +8.5% | -1.2% |
No insider trades available.
8-K · 7.01
! Medium
Aldeyra Therapeutics, Inc. -- 8-K 7.01: Regulation FD Disclosure
Aldeyra Therapeutics disclosed updated clinical trial data and FDA feedback on its reproxalap dry eye disease treatment, providing transparency on efficacy endpoints and regulatory progress toward potential market approval.
May 1
8-K · 5.02
!!! Very High
Aldeyra Therapeutics, Inc. -- 8-K 5.02: Executive Change
Aldeyra Therapeutics' board member Martin J. Joyce will not seek re-election, representing a leadership transition that investors should monitor for potential strategic implications.
Apr 20
8-K
Unknown — 8-K Filing
I cannot provide a meaningful analysis because the filing summary describes only technical XBRL metadata and form structure rather than actual company events or financial disclosures that would impact stock valuations.
Apr 1
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Aldeyra's dry eye disease drug failed FDA approval due to inconsistent efficacy data, eliminating a key pipeline asset and likely pressuring the stock significantly given the clinical setback.
Mar 17
Data updated apr 24, 2026 5:11pm
· Source: massive.com